APM
ADAP

Avidity Partners Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Avidity Partners Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,084,700
Closed -$16.6M – 98
2020
Q3 		$16.6M Buy
2,084,700
+646,700
+45% +$5.66M 0.77% 40
2020
Q2 		$14.4M Buy
+1,438,000
New +$9.03M 0.92% 42

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Avidity Partners Management's ADAP Position: Q4 2020 in Review

Avidity Partners Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2020, closing a stake of 2,084,700 shares — an estimated $16.6M sold.

Avidity Partners Management first reported a position in ADAP in Q2 2020 and held it in 2 quarters. The position peaked at $16.6M in Q3 2020. 87 funds tracked by Wall St. Rank hold ADAP as of Q4 2020.

  • Avidity Partners Management reported no remaining Adaptimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Avidity Partners Management sold 2,084,700 Adaptimmune Therapeutics shares in Q4 2020, an estimated $16.6M.
  • Avidity Partners Management first reported a position in Adaptimmune Therapeutics in Q2 2020 and held it in 2 quarters.
  • Avidity Partners Management's Adaptimmune Therapeutics position peaked at $16.6M in Q3 2020.
  • 87 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2020.

Based on Avidity Partners Management's 13F filing for Q4 2020, filed 16 Feb 2021.